| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES Principles of Consolidation The accompanying consolidated financial
statements include the accounts of our company and our wholly owned subsidiaries, vitaMed, BocaGreen and VitaCare. All intercompany
balances and transactions have been eliminated in consolidation. Risks and Uncertainties We continue to be subject to risks and
uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues
to be highly uncertain and difficult to predict. We continue to provide an uninterrupted supply of our portfolio of products for
patients. We have sufficient inventory of finished product to meet anticipated demand in the near future. Additionally, we currently
do not foresee any interruption in our ability to continue to manufacture additional product to be used beyond this period and
have sufficient active pharmaceutical ingredients on hand for the continued manufacture of our products. During the year ended
December 31, 2020, we recorded an inventory charge of $ 7,204,818 Since the early phase of the COVID-19 pandemic,
we have been using substantial virtual options to ensure business continuity. Our VitaCare Prescription Services patient model
assists patients in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice,
including via home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple
third-party online pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time
access to both diagnosis and treatment. We continue to support prescribers’ needs with samples and product materials through
our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for live virtual e-detailing of our products. As part of our response to the COVID-19
pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented cost saving measures, which included
negotiating lower fees or suspending services from third party vendors; implementing a company-wide hiring restriction; delaying
or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event
expenses. The full impact of the COVID-19 pandemic
continues to evolve. However, we remain committed to the execution of our corporate goals, despite the ongoing COVID-19 pandemic,
as demonstrated in part by the increase in product revenue throughout 2020. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity,
or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our operations by monitoring
the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic
has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression
that has occurred or may occur in the future. While we currently believe that our COVID-19
contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our business, the severity of the impact of
the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity
of the pandemic, the duration of “social distancing” orders, the ability of our sales force to access healthcare providers
to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients,
thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which are uncertain.
Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable
amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs
that we may undertake to address financial and operations challenges that we may face. Liquidity As of the filing date of this Annual
Report on Form 10-K, our cash balance was above the required balance by the Financing Agreement (as defined in Note 8 -
Debt). On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing Agreement, or Amendment No.
6, with the Administrative Agent (as defined in Note 8 - Debt) and the lenders party thereto, pursuant to which we
temporarily lowered the minimum required cash balance from $ 60 45 60 However, if we are unsuccessful with the
commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if commercialization is delayed, or if the continued impact of the COVID-19
pandemic on our business is worse than we anticipate, our existing cash reserves may be insufficient to maintain compliance with
the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY,
BIJUVA, and ANNOVERA. The Financing Agreement also requires us to maintain certain minimum quarterly product net revenue requirements
and several other restrictive covenants. On March 1, 2021, we entered into Amendment No. 8 to the Financing Agreement, or Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA were revised. See Note 8 – Debt – for a description
of these covenants. These and other terms in the Financing Agreement have to be monitored closely for compliance
and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.
If we are unable to maintain the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements,
or otherwise comply with the covenants of the Financing Agreement, all or a portion of our obligations under the Financing Agreement
may be declared immediately due and payable, which would have a material adverse effect on our business, results of operations
and financial condition. Cash We maintain cash at financial institutions
that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $ 250,000 Trade Accounts Receivable and Allowance
for Doubtful Accounts Trade accounts receivable are customer
obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks
and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection
information, reasonable supportable forecasts, and existing economic conditions and we record an allowance that presents the net
amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent receivables against
our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances
of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful
accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves
may be required. Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws,
coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption
associated with the current COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced
significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying
amount of trade receivables in the future. At December 31, 2020, four different customers represented 25 19 17 11 36 21 16 11 The opening balance of the allowance for doubtful accounts is
reconciled to the closing balance for expected credit losses as follows:
Allowance for Doubtful Accounts
Balance - January 1, 2020 $ 904,040
Increase in allowance 422,137
Recoveries (181,514 )
Write-offs (26,809 )
Balance - December 31, 2020 $ 1,117,854 Inventories Inventories represent pharmaceutical products,
packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products
are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for
excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value.
Obsolescence may occur due to product expiring, product improvements rendering previous versions obsolete, or decreases in demand
for our products. Pre-Launch Inventory Pre-launch inventory costs associated with
product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial
use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined,
then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during
the period the costs are incurred. We have not capitalized any pre-launch inventory to date. Inventory Write-Off We evaluate inventory quarterly for short
dated and excess inventory. During the years ended December 31, 2020 and December 31, 2019, we recorded an inventory charge of
$ 7,204,818 0 Cost of Sales Cost of sales includes the cost of inventory,
manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. The Population Council License
Agreement requires payment of royalties based on the sale of future products. Such royalties are recorded as a component of cost
of sales. Additionally, the amortization of license fees or milestone payments related to licensed products are classified as components
of cost of sales to the extent such payments become due in the future. Fixed Assets We state fixed assets at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives
of the related assets, which range from three seven years We capitalize software and software development
costs incurred to create and acquire computer software for internal use, principally related to software coding and application
development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable
that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized
in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into
service over the estimated useful life, generally five seven years Intangible Assets We have adopted the provisions of Financial
Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, Intangibles - Goodwill and Other 38 39 Impairment of Long-Lived Assets We review the carrying values of fixed
assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate
that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:
● significant declines in an asset’s market price;
● significant deterioration in an asset’s physical condition;
● significant changes in the nature or extent of an asset’s use or operation;
● significant adverse changes in the business climate that could impact an asset’s value, including
adverse actions or assessments by regulators;
● accumulation of costs significantly in excess of original expectations related to the acquisition
or construction of an asset;
● current-period operating or cash flow losses combined with a history of such losses or a forecast
that demonstrates continuing losses associated with an asset’s use; and
● expectations that it is more likely than not that an asset will be sold or otherwise disposed of
significantly before the end of its previously estimated useful life. If impairment indicators are present, we
determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value
for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are
largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate
the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate
to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise
of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held
and used. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’
fair value and respective carrying values. We determine the fair value of the assets using an “income approach” based
upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant
estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount
rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information
about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and
changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. We perform impairment tests for intangible
assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change
that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for
assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying
amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. We also evaluate the remaining useful life
of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment
or warrant a revision to the remaining useful life. If the estimate of an intangible asset’s remaining useful life is changed,
we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life. The fair value of indefinite-lived assets
is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment
test. During the years ended December 31, 2020 and 2019, we wrote off $ 1,131,776 78,864 Fair Value of Financial Instruments Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of December 31, 2020 and
2019 (as disclosed in Note 8) approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2). We categorize our assets and liabilities
that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, Fair Value
Measurements, .
Level 1 unadjusted quoted prices in active markets for identical
assets or liabilities;
Level 2 quoted prices for similar assets or liabilities in active
markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and
Level 3 unobservable inputs for the assets or liabilities. At December 31, 2020 and 2019, we had no assets or liabilities
that were valued at fair value on a recurring basis. Income Taxes We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized. In accordance with ASC 740, Income Taxes We recognize both interest and penalties
related to uncertain tax positions as part of the income tax provision. At December 31, 2020 and 2019, we had no tax positions
relating to open tax returns that were considered to be uncertain. Our U.S. federal and state tax returns
since 2011, which was the first year we generated net operating losses, remain open to examination. Share-Based Compensation We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation We grant restricted stock units and performance-based
stock units for shares of common stock, par value $ 0.001 Revenue Recognition In accordance with ASC 606, Revenue
from Contracts with Customers Prescription Products As of December
31, 2020, We sell our name brand and generic prescription
products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription
products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations
related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service
for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription
product revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or
service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the
customer’s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on
our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional.
We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services
sold by us is typically due between 30 and 60 days after an invoice is sent to the customer. The transaction price of a contract is
the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative product revenue recognized will
not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract’s transaction price, we rely on our historical experience and other evidence that
supports our qualitative assessment of whether product revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a product revenue reversal arising from an uncertain future event and
the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ
from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would
affect net product revenue and earnings in the period such changes in estimates become known. We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of six months prior to and up to 12 12 24 18 We offer various rebate and discount programs in an effort to maintain
a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates
and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on
a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenue at the time the product
revenue is recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor
fees are recorded in other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units
sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors
fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates
relating to invoice discounts and chargebacks are deducted from gross product revenue at the time the product revenue is recognized. As part of commercial launches for our
FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket
costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with
our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. The variable consideration
is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average
assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients’ insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time
up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription
products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain
variable consideration for our prescription products to an amount that will not result in a significant product revenue reversal
in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates
of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by
insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently
available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period. Disaggregation of revenue The following table provides information
about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:
For the Years Ended December 31,
2020 2019 2018
Prescription vitamins $ 9,767,644 $ 9,885,493 $ 15,041,259
IMVEXXY 27,139,387 16,252,045 1,058,201
BIJUVA 6,353,963 1,836,443 —
ANNOVERA 19,611,286 6,166,556 —
License revenue 2,000,000 15,506,400 —
Net revenue $ 64,872,280 $ 49,646,937 $ 16,099,460 License Revenue License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front
fees that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the right to use functional intellectual property is transferred to the customer. License Agreement with the Population
Council On July 30, 2018, we entered into the Population
Council License Agreement to commercialize ANNOVERA in the U.S. We began selling ANNOVERA in a “test and learn” market
introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We
resumed the commercial launch of ANNOVERA on July 1, 2020. Under the terms of the Population Council
License Agreement, we paid the Population Council a milestone payment of $ 20,000,000 20,000,000 20,000,000 3,024,391 778,692 The Population Council is also eligible
to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible for marketing expenses related
to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council, on a quarterly basis, step-based
royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates and permitted licensees as
follows: (i) if annual net sales are less than or equal to $ 50,000,000 5 50,000,000 150,000,000 10 150,000,000 15 50 20 40 200 400 1 20,000,000 Unless earlier terminated, the Population
Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council’s
U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during
which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may
also be terminated for certain breach and bankruptcy-related events and by us on 180 days’ prior notice to the Population
Council. License Agreement with Knight Therapeutics
Inc. In July 2018, we entered into the Knight
License Agreement pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.
Pursuant to the terms of the Knight License Agreement, Knight paid us $ 2,000,000 License Agreement with Theramex On June
6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR 14 15,506,400 2
million 27.5
million Territory
ranging from EUR 25 100 5 Territory. Theramex is responsible for
all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory.
Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all
regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA
and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex
challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party
that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. Segment Reporting We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single executive leadership team that is led by the Chief Executive Officer of our Company, who oversees all operations. We do
not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information
with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business
as one reportable operating segment. Shipping and Handling Costs We expense all shipping and handling costs
as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements. Advertising Costs We expense advertising costs when incurred.
Advertising costs were $ 35,799,313 9,045,571 1,682,746 Research and Development Expenses Research and development, or R&D, expenses
include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, manufacturing, scale-up and validation costs, and other activities. Internal R&D activity expenses include laboratory
supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory
experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken
by our regulatory consultants that were classified as R&D expenses include assisting, consulting with, and advising our in-house
staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking
work for our clinical trials and investigative drugs. We charge internal R&D activities and other activity expenses to operations
as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date.
We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity
has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses
and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion
stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion.
We charge revisions to expenses in the period in which the facts that give rise to the revision become known. Earnings Per Share We calculate earnings per share, or EPS,
in accordance with ASC 260, Earnings Pe |
